|Videos|April 14, 2022

Investigational oral agent noninferior to intravenous ertapenem for complicated UTIs

“Oral tebipenem pivoxil hydrobromide and intravenous ertapenem had a similar safety and tolerability profile,” says Angela Talley, MD.

In this video, Angela Talley, MD, discusses the background and notable findings of the recent New England Journal of Medicine paper, “Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection,” for which she served as senior author. Talley is senior vice president of Clinical Development at Spero Therapeutics.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME